original ) (raw )Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program
Otavio Cintra
Vaccine, 2016
View PDFchevron_right
Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil
Lane Alencar
Emerging Infectious Diseases, 2013
View PDFchevron_right
Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina
Gustavo Cesar Ezcurra
Journal of the Pediatric Infectious Diseases Society, 2017
View PDFchevron_right
A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil
Michael Pride
Vaccine, 2012
View PDFchevron_right
Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands
Robert Welte
Clinical Therapeutics, 2003
View PDFchevron_right
Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial
Yetunde Kuyinu
BMC Public Health, 2011
View PDFchevron_right
Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All
Vana Spoulou
Vaccines, 2021
View PDFchevron_right
Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age
Alessandro Lizioli
Respiratory research, 2007
View PDFchevron_right
Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil
Ana Freitas Ribeiro
Vaccine, 2016
View PDFchevron_right
Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial
Ana Leandro , Eduardo Ortega-Barria
PLoS medicine, 2014
View PDFchevron_right
Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children
Yetunde Kuyinu
Human Vaccines & Immunotherapeutics, 2013
View PDFchevron_right
Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
Michel Moutschen
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015
View PDFchevron_right
Current Recommendations for Pneumococcal Vaccination of Children and Adults
Alireza nateghian
Tanaffos, 2015
View PDFchevron_right
Changes in the incidence of pneumonia, bacterial meningitis, and infant mortality 5 years following introduction of the 13-valent pneumococcal conjugate vaccine in a "3+0" schedule
Julio Rocha
PloS one, 2017
View PDFchevron_right
Impact of the antipneumococcal conjugate vaccine on the occurrence of infectious respiratory diseases and hospitalization rates in children
Altacílio Nunes
Revista da Sociedade Brasileira de Medicina Tropical
View PDFchevron_right
Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil
Andre Kipnis
PloS one, 2014
View PDFchevron_right
Effect of pneumococcal conjugate vaccine introduction on childhood pneumonia mortality in Brazil: a retrospective observational study
Lone Simonsen
The Lancet Global Health, 2019
View PDFchevron_right
Pneumococcal vaccines for children: a global public health priority
Klara PosfayBarbe
Clinical Microbiology and Infection, 2012
View PDFchevron_right
Pneumococcal Pneumonia in Hospitalized Uruguayan Children and Potential Prevention with Different Vaccine Formulations
Miguel Estevan , Teresa Camou
The Journal of Pediatrics, 2008
View PDFchevron_right
Appropriateness of a Pneumococcal Conjugate Vaccine in Brazil: Potential Impact of Age and Clinical Diagnosis, with Emphasis on Meningitis
Jose Luis Di Fabio
The Journal of Infectious Diseases, 2003
View PDFchevron_right
Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
Jorge Ávila Gómez
Human Vaccines & Immunotherapeutics, 2021
View PDFchevron_right
Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial
Patricia Lommel
Vaccine, 2018
View PDFchevron_right
Impact of Universal Pneumococcal Vaccination on Hospitalizations for Pneumonia and Meningitis in Children in Montevideo, Uruguay
Adriana Varela
The Pediatric Infectious Disease Journal, 2011
View PDFchevron_right
Risk factors for community-acquired pneumonia in children under five years of age in the post-pneumococcal conjugate vaccine era in Brazil: a case control study
Jailson Correia
BMC pediatrics, 2016
View PDFchevron_right
Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial
Arto Palmu
The Lancet Respiratory Medicine, 2014
View PDFchevron_right
Effect of 7 and 13-Valent Pneumococcal Conjugate Vaccines Different Number of Doses for Pneumonia Control in 2008 and 2010 Birth Cohort Children
Fernando Arrieta
World Journal of Vaccines, 2015
View PDFchevron_right
Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England
Timothy Harrison
2014
View PDFchevron_right